好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Diagnostic, Treatment, and Follow-up Practice Variation in Encephalitis of Unknown Etiology: The Neuroinfections Emerging in the Americas Study (NEAS) In Colombia
Autoimmune Neurology
P3 - Poster Session 3 (11:30 AM-12:30 PM)
1-028

To characterize variation in diagnostic testing, autoimmune workup, treatment, and follow-up across hospitals in the Neuroinfections Emerging in the Americas Study (NEAS) cohort in Colombia.

Encephalitis of unknown etiology requires timely identification of treatable infectious and autoimmune causes. A mixed public-private system delivers care across Colombian cities of varying sizes, most within arbovirus-endemic zones (dengue, Zika, chikungunya). Uneven diagnostic infrastructure and absence of harmonized institutional protocols may allow hospital context to shape evaluation, treatment, and follow-up.

Patients diagnosed with encephalitis of unknown etiology were enrolled in an observational cohort at 12 Colombian high-complexity hospitals, 2016–2025 (N=127). Hospitals were classified by ownership (public [N=76]; private [N=51]) and metropolitan size (large ≥1M [N=82]; intermediate <1M [N=45]).

Cerebrospinal fluid (CSF) analysis was performed in 118 (93%), with herpes simplex virus (HSV) PCR ordered in 63 (53%) of those. Among all 127 patients, acyclovir was administered empirically to 55 (43%), steroids to 31 (24%), intravenous immunoglobulin and plasmapheresis each to 4 (3%). Private hospitals had higher magnetic resonance imaging (MRI) rates than public hospitals (73% vs 51%, p=0.026). Intermediate-city hospitals had higher CSF analysis rates (100% vs 89%, p=0.026), head computed tomography (CT) (84% vs 63%, p=0.014), and electroencephalogram (EEG) (61% vs 24%, p<0.001); large-metro hospitals had shorter time to MRI (median 1 vs 4 days, p=0.006). MRI, EEG, and CT rates varied across hospitals (p≤0.020). Clinical follow-up rate was higher in large-metro than intermediate-city hospitals (72% vs 16%, p<0.001).

Diagnostic practice, autoimmune workup, and clinical follow-up varied by hospital ownership and metropolitan size. Molecular microbiology testing and immunotherapy use were low across settings, and follow-up was documented in fewer than 1 in 6 patients at intermediate-city hospitals. These patterns are consistent with context-dependent decision-making shaped by structural and geographic factors; standardized diagnostic and follow-up protocols could support more consistent care throughout.

Authors/Disclosures
Maria I. Reyes, MD (Hospital Simon Bolivar)
PRESENTER
Dr. Reyes has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Reyes has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Reyes has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Reyes has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Reyes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Reyes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.
Sebastian Jimenez, BS Mr. Jimenez has nothing to disclose.
Guillermo Gonzalez-Manrique Guillermo Gonzalez-Manrique has nothing to disclose.
David Acero-Garces, MD Dr. Acero-Garces has nothing to disclose.
Beatriz Parra Beatriz Parra has nothing to disclose.
Lyda Osorio Lyda Osorio has nothing to disclose.
Federico Silva (Fundacion Cardiovascular De Colombia) Federico Silva has nothing to disclose.
Jairo Lizarazo Niño Jairo Lizarazo Niño has nothing to disclose.
Carlos A. Pardo-Villamizar, MD (Johns Hopkins U, Med Dept of Neurology) The institution of Dr. Pardo-Villamizar has received research support from National Institutes of Health. The institution of Dr. Pardo-Villamizar has received research support from Bart McLean Fund for Neuroimmunology Research .